@lcrf.orgAmong those presenting today at #WCLC26 in Seoul, South Korea: LCRF Scientific Advisory Board Members Dr. Christine Bestvina and Dr. Karen Reckamp; LCRF grantee Dr. Xiuning Le; and LCRF Together New York panelist Dr. Balazs Halmos.
#LungCancer @balazshalmos.bsky.social
@btog.bsky.socialSelected key takeaway from our 2026 Annual Conference: How Are We Doing? Results of the BTS Pilot Audit presented by Emma O’Dowd. Full recordings and presentations available to members on our website. #LCSM #lungcancer
@thecancersurvivorsclub.comPrecision medicine continues to change lung cancer care. For some patients with EGFR-mutated lung cancer, targeted treatment after surgery can reduce recurrence risk and improve survival.
@cancers-mdpi.bsky.social🤗We were delighted to meet with our editors in person at #WCLC2026!
Thank you for the insightful conversations and continued support in advancing high-quality research in lung cancer✨
#LungCancer #ThoracicOncology #CancersMDPI
@lcrf.orgWhen Glenna was told she had stage 4 #LungCancer, she wasn’t sure what the future held. Today? She and her husband, Chris, are planning their next milestone anniversary trip. "When I was diagnosed in 2023, I only had two treatment options. Now there are more—but we can’t stop there." LCRF.org/fall26
@megadoctornews.comNew AI Tool Accurately Predicts Lung Cancer Immunotherapy Results #ai #ArtificialIntelligence #cancer #CancerTreatment #immunotherapy #LungCancer https://megadoctornews.com/new-ai-tool-accurately-predicts-lung-cancer-immunotherapy-results/
@bestsurvivor.bsky.socialThe test currently costs about $60. Research was led by Prof. Yuval Ebenstein of Tel Aviv University, with scientists and doctors from JaxBio Technologies, Bnai Zion Medical Center, Sheba Medical Center, and other institutions.
#LungCancer
#Israel
@lcrf.orgThank you to Bayer for your generosity and support as National Presenting Sponsor for the Free to Breathe events program! #FreeToBreathe #LungCancer #ThankYou
@pharmaphorum.bsky.social#GSK reported good #clinicaltrialresults with two of its #lungcancer therapies – #Jideytro and #risvutatugrezetecan (ris-rez) – at the ongoing #WCLC congress in #Seoul, South Korea.
@lcrf.orgAmong those presenting today at #WCLC26 in Seoul, South Korea: LCRF Team Science grantee Dr. David Barbie; LCRF Scientific Advisory Board member Dr. Misako Nagasaka; and LCRF Education + Engagement Committee member Dr. Eric Singhi (twice).
#LungCancer @lungoncdoc.bsky.social
@medchemexpress.bsky.social💊 #WCLC 2026 | Key Advances in #LungCancer Research
From B7-H3 ADCs to next-generation TKIs and combination strategies, WCLC 2026 highlights evolving approaches in #NSCLC and #SCLC:
🔗https://bit.ly/4xW10sT
@lcrf.orgAmong those presenting today at the World Conference on Lung Cancer in Seoul, South Korea: LCRF grantees Dr. Jaime Schneider, Dr. Hilary Robbins, Dr. Benjamin Lok, and Dr. Christian Rolfo (twice!).
@rcatanho.bsky.socialCuantificación automatizada 3D de la TAC de dosis baja permite estratificación dirigida por inteligencia artificial más allá de los factores tradicionales, lo que apoya la prevención personalizada en las poblaciones de alto riesgo #AI #CT #LungCancer ascopubs.org/doi/abs/10.1...
@southamptonctu.bsky.socialOur Director, Professor Gareth Griffiths, is at the World Conference on #LungCancer this week, presenting posters on our SELECTmeso and TOURIST #ClinicalTrial platforms.
If you're at #WCLC, do go and chat with Gareth to find out more!
@nihr.bsky.social @asthmaandlung.org.uk @mesouk.bsky.social
@thecancersurvivorsclub.comMore encouraging lung cancer research. Tagrisso plus Orpathys significantly improved progression-free survival in a Phase 3 trial for patients with advanced EGFR-mutated lung cancer and MET overexpression.
@thecancersurvivorsclub.comLong-term survival continues to improve for some people with EGFR-mutated lung cancer. Tagrisso has produced encouraging long-term survival results following surgery for early-stage disease.
@trackerbiobank.bsky.social🌏🔬 TRACKER PhD Candidate Dr Sarah Yeo is in Seoul for #WCLC2026, supported by the Rosemary Holmes Travel Grant from Lung Foundation Australia
If you’re at WCLC, make sure to catch Sarah presenting in the Pathology & Biomarker session today!
@meridia.newsGood News of the Day: Zidesamtinib shrank tumors in 93% of patients with ROS1-positive lung cancer in a global trial. A promising new option for advanced cases. #LungCancer #Hope
#GoodNews #PositiveNews #HealthNews #Wellness #MedicalBreakthrough
@cancers-mdpi.bsky.social📸 Great catching up with so many esteemed researchers and experts in the lung cancer community at #WCLC2026!
If you are at the conference, drop by booth #706 to connect with our team! ✨
#LungCancer #CancersMDPI #Oncology @iaslc.bsky.social
